Comparative study between Nano-surface Polyzene F and drug eluting stents in acute coronary syndrome patients with one-month dual antiplatelet therapy: Immediate and one-year clinical outcome.
Arnous, H., Eltahhan, M., Ahmad, T., Fahmy, A., Sallam, M. (2644). Comparative study between Nano-surface Polyzene F and drug eluting stents in acute coronary syndrome patients with one-month dual antiplatelet therapy: Immediate and one-year clinical outcome.. EKB Journal Management System, 2023(1), -. doi: 10.58675/2682-339X.1717
Hazem Arnous; Mamdouh Eltahhan; Taghreed Ahmad; Ahmad Fahmy; Mansour . Sallam. "Comparative study between Nano-surface Polyzene F and drug eluting stents in acute coronary syndrome patients with one-month dual antiplatelet therapy: Immediate and one-year clinical outcome.". EKB Journal Management System, 2023, 1, 2644, -. doi: 10.58675/2682-339X.1717
Arnous, H., Eltahhan, M., Ahmad, T., Fahmy, A., Sallam, M. (2644). 'Comparative study between Nano-surface Polyzene F and drug eluting stents in acute coronary syndrome patients with one-month dual antiplatelet therapy: Immediate and one-year clinical outcome.', EKB Journal Management System, 2023(1), pp. -. doi: 10.58675/2682-339X.1717
Arnous, H., Eltahhan, M., Ahmad, T., Fahmy, A., Sallam, M. Comparative study between Nano-surface Polyzene F and drug eluting stents in acute coronary syndrome patients with one-month dual antiplatelet therapy: Immediate and one-year clinical outcome.. EKB Journal Management System, 2644; 2023(1): -. doi: 10.58675/2682-339X.1717

Comparative study between Nano-surface Polyzene F and drug eluting stents in acute coronary syndrome patients with one-month dual antiplatelet therapy: Immediate and one-year clinical outcome.

Al-Azhar International Medical Journal
Volume 2023, Issue 1, January 2023
DOI: 10.58675/2682-339X.1717
Authors
Hazem Arnous1; Mamdouh Eltahhan2; Taghreed Ahmad2; Ahmad Fahmy2; Mansour . Sallam2
1Department of Cardiology, Nasser Institute, Ministry of Health, Egypt.
2Department of Cardiology, Faculty of Medicine – Al-Azhar University, Cairo, Egypt.
Abstract
Background and objectives: The current clinical practice advocates dual antiplatelet therapy (DAPT) for a year after ST segment elevation myocardial infarction (STEMI), primarily owing to persistent thrombotic risk. The novel COBRA PzF coronary stent was developed to reduce stent thrombosis risk. The primary goal of the current research was to compare the efficacy and safety of the novel nanocoated PzF stenting with one-month DAPT (dual anti-platelet therapy) against 12-month DAPT after the current drug- eluting stent (DES) in STEMI patients and single-vessel coronary artery disease (CAD). Patients & methods: A prospective observational study enrolled 100 cases presented with STEMI and single vessel CAD. Eligible patients were allocated into 2 groups; group I consisted of 50 patients managed with the COBRA PzF stent who received one-month DAPT. Group II consisted of 50 patients treated with DES who received one-year DAPT. The occurrence of stent thrombosis was our primary endpoint. The secondary endpoints were target vessel revascularization and major adverse cerebro-cardiovascular occurrences throughout the year. Results: There were no observed cases of definite stent thrombosis in group I against three in group II, however, it didn’t reach statistical significance (p=0.094) The incidence of target vessel revascularization (6% against 10%), death (2% versus 4%), stroke (0 versus 2%) and major bleeding (0% versus 4%) observed in group I and II respectively, however, it didn’t reach statistical significance. Conclusion: The COBRA Polyzene-F stent with one-month DAPT met the performance goals for stent thrombosis in patients presenting with STEMI with single vessel CAD and compared favorably with the commercially available DES with one-year DAPT.
Statistics
Article View: 10